Nanoviricides Inc (NNVC) 2.02 $NNVC
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model
PR Newswire - Mon Apr 20, 6:00AM CDT
NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. He is a leading researcher in herpes virus anti-viral agents and vaccines.
NNVC: 2.02 (-0.02)
NanoViricides Provides an Update on Its Progress over the Last Quarter
PR Newswire - Mon Apr 06, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reports on the Company's progress in the recent quarter.
BASI: 2.05 (-0.02), NNVC: 2.02 (-0.02)
H3N2 Infection Therapeutics Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/txhmv4/h3n2_infection) has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - Colby Pharmaceutical Company - Crucell N.V. - Cure Lab, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - NanoViricides, Inc. - REPLICor Inc. - Takeda Pharmaceutical Company Limited - Vaxart, Inc. Drug Profiles - Aspidasept - AVX-502 - bordetella pertussis [strain BPZE1] vaccine - C-05 - CLVax-1.0 - CR-9114 - Gamma-Flu - ID-38 - influenza [H3N2] vaccine - influenza vaccine - JVRS-100 influenza [H1N1/H3N2] vaccine - NVINF-1 - NVINF-2 - REP-9 - seasonal influenza [H3N2] vaccine - VX-787 For more information visit http://www.researchandmarkets.com/research/tx..._infection
JNJ: 100.43 (+0.13), INO: 10.38 (-0.10), NNVC: 2.02 (-0.02)
NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders
PR Newswire - Mon Mar 09, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , reported that it has completed the registration of 571,433 shares of the Company's common stock to be issued as interest to holders of the Company's Unsecured 8% Coupon Series B Convertible Debentures (the "Debentures" .
NNVC: 2.02 (-0.02)
Warts Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Tue Mar 03, 6:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8btxq/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - Agilvax, Inc. - Anaconda Pharma - BioMAS Ltd. - Burke Pharmaceuticals, LLC - Cutanea Life Sciences - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - NanoViricides, Inc. - Nielsen Biosciences, Inc. - ViroStatics, srl Drug Profiles - (digoxin furosemide) - 854-A - A-101 - AP-611074 - AS-101 - AX-03 - BURKE-201 - Candida Albicans Antigen - HerpeCide-I - imiquimod - interferon alpha-2b (recombinant) - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - SRT-100 For more information visit http://www.researchandmarkets.com/research/h8...s_pipeline
FOMX: 10.94 (-0.02), NNVC: 2.02 (-0.02)
NanoViricides reports FQ2 results
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
NNVC: 2.02 (-0.02)
NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Investment Bank
PR Newswire - Tue Feb 17, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported that Midtown Partners, Inc., ("Midtown" has published a research report on NanoViricides on February 11, 2014, according to Midtown's website. The report can be found on their website at http://www.midtownpartners.com under the "Research" tab.
NNVC: 2.02 (-0.02)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 10.38 (-0.10), JNJ: 100.43 (+0.13), BCRX: 10.62 (-0.09), HEB: 0.25 (+0.01), NLNK: 53.12 (-0.07), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02), GSK: 46.57 (-0.67)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 33.73 (-0.05), JNJ: 100.43 (+0.13), UTHR: 187.98 (+0.12), MRK: 57.69 (+0.03), NNVC: 2.02 (-0.02), GSK: 46.57 (-0.67), SIGA: 2.05 (-0.21)
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi
PR Newswire - Fri Jan 23, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
NNVC: 2.02 (-0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 7.92 (+0.37), CRIS: 2.88 (+0.09), NES: 3.52 (-0.15), TZOO: 13.06 (-0.02), WLT: 0.57 (-0.01), FXCM: 2.13 (+0.02), NNVC: 2.02 (-0.02), VLTC: 15.14 (-1.04), CYN: 93.19 (+0.06), ANR: 0.84 (-0.01), OTIC: 32.83 (unch), MHR: 2.34 (-0.07), EGLT: 10.34 (-0.27), NERV: 5.68 (+0.05), FFIV: 120.42 (+1.49), KEG: 2.15 (+0.03), CTP: 3.89 (+0.08), ENRJ: 1.75 (+0.05), LE: 29.96 (-0.13)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 10.38 (-0.10), BCRX: 10.62 (-0.09), CMRX: 39.73 (+0.65), HEB: 0.25 (+0.01), SRPT: 13.52 (+0.04), ABIO: 0.88 (+0.01), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02)
NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
PR Newswire - Thu Jan 22, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment.
NNVC: 2.02 (-0.02)
NanoViricides announces purchase of common stock by insiders
M2 - Thu Jan 22, 5:29AM CST
Nanomaterials antiviral company NanoViricides (NYSE MKT:NNVC) said on Wednesday that its executives purchased 62,392 shares of its common stock in uncoordinated open market purchases during its open trading windows for insiders.
NNVC: 2.02 (-0.02)
NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock
PR Newswire - Wed Jan 21, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders.
NNVC: 2.02 (-0.02)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 2.37 (-0.02), STZ: 115.99 (-1.30), CRDS: 2.58 (-0.02), PETX: 16.15 (+0.01), NNVC: 2.02 (-0.02), RM: 14.75 (+0.24), ALL: 70.88 (+0.06), TNET: 35.45 (-0.54), SFST: 17.51 (-0.24), AGEN: 6.08 (+0.21), GES: 18.14 (+0.11), WIW: 11.45 (unch), LRCX: 78.36 (+0.52), COST: 146.98 (-0.36), EBF: 14.00 (+0.17), TWTR: 51.73 (+0.41), JGW: 10.70 (+0.24), WIA: 11.60 (-0.04)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 44.60 (-0.22), RTN: 109.65 (+0.82), AERI: 34.42 (-0.70), MRD: 19.19 (+0.06), ADX: 14.17 (+0.06), LTS: 3.56 (unch), NNVC: 2.02 (-0.02), ARDX: 12.51 (-0.01), PANW: 153.87 (-0.50), CTRE: 13.39 (-0.24), PCTY: 31.29 (+0.64), BH: 396.99 (-5.47), WIW: 11.45 (unch), SNCR: 51.87 (+0.02), OPK: 14.60 (+0.17), UBA: 20.99 (-0.13), WIA: 11.60 (-0.04)
NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
PR Newswire - Wed Jan 07, 6:30AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC.
NNVC: 2.02 (-0.02)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.02), NNVC: 2.02 (-0.02)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.62 (-0.09), VSR: 3.51 (+0.05), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02), INO: 10.38 (-0.10), CMRX: 39.73 (+0.65), APT: 2.19 (unch), HEB: 0.25 (+0.01), SRPT: 13.52 (+0.04), SMED: 6.84 (+0.01), PLX: 2.08 (+0.02), NLNK: 53.12 (-0.07), LAKE: 9.56 (-0.01), NSPH: 4.05 (+0.10)
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model
PR Newswire - Mon Apr 20, 6:00AM CDT
NanoViricides, Inc., (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. He is a leading researcher in herpes virus anti-viral agents and vaccines. NNVC: 2.02 (-0.02)
NanoViricides Provides an Update on Its Progress over the Last Quarter
PR Newswire - Mon Apr 06, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reports on the Company's progress in the recent quarter. BASI: 2.05 (-0.02), NNVC: 2.02 (-0.02)
H3N2 Infection Therapeutics Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Wed Mar 25, 12:05PM CDT
Research and Markets (http://www.researchandmarkets.com/research/txhmv4/h3n2_infection) has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - Colby Pharmaceutical Company - Crucell N.V. - Cure Lab, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - NanoViricides, Inc. - REPLICor Inc. - Takeda Pharmaceutical Company Limited - Vaxart, Inc. Drug Profiles - Aspidasept - AVX-502 - bordetella pertussis [strain BPZE1] vaccine - C-05 - CLVax-1.0 - CR-9114 - Gamma-Flu - ID-38 - influenza [H3N2] vaccine - influenza vaccine - JVRS-100 influenza [H1N1/H3N2] vaccine - NVINF-1 - NVINF-2 - REP-9 - seasonal influenza [H3N2] vaccine - VX-787 For more information visit http://www.researchandmarkets.com/research/tx..._infection
JNJ: 100.43 (+0.13), INO: 10.38 (-0.10), NNVC: 2.02 (-0.02)
NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders
PR Newswire - Mon Mar 09, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, reported that it has completed the registration of 571,433 shares of the Company's common stock to be issued as interest to holders of the Company's Unsecured 8% Coupon Series B Convertible Debentures (the "Debentures" . NNVC: 2.02 (-0.02)
Warts Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Tue Mar 03, 6:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8btxq/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3M Drug Delivery Systems - Agilvax, Inc. - Anaconda Pharma - BioMAS Ltd. - Burke Pharmaceuticals, LLC - Cutanea Life Sciences - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - NanoViricides, Inc. - Nielsen Biosciences, Inc. - ViroStatics, srl Drug Profiles - (digoxin furosemide) - 854-A - A-101 - AP-611074 - AS-101 - AX-03 - BURKE-201 - Candida Albicans Antigen - HerpeCide-I - imiquimod - interferon alpha-2b (recombinant) - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - SRT-100 For more information visit http://www.researchandmarkets.com/research/h8...s_pipeline
FOMX: 10.94 (-0.02), NNVC: 2.02 (-0.02)
NanoViricides reports FQ2 results
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
NNVC: 2.02 (-0.02)
NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Investment Bank
PR Newswire - Tue Feb 17, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported that Midtown Partners, Inc., ("Midtown" has published a research report on NanoViricides on February 11, 2014, according to Midtown's website. The report can be found on their website at http://www.midtownpartners.com under the "Research" tab. NNVC: 2.02 (-0.02)
U.S. to pull troops from Ebola zone
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:38AM CST
INO: 10.38 (-0.10), JNJ: 100.43 (+0.13), BCRX: 10.62 (-0.09), HEB: 0.25 (+0.01), NLNK: 53.12 (-0.07), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02), GSK: 46.57 (-0.67)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 33.73 (-0.05), JNJ: 100.43 (+0.13), UTHR: 187.98 (+0.12), MRK: 57.69 (+0.03), NNVC: 2.02 (-0.02), GSK: 46.57 (-0.67), SIGA: 2.05 (-0.21)
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi
PR Newswire - Fri Jan 23, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline. NNVC: 2.02 (-0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:45AM CST
HSGX: 7.92 (+0.37), CRIS: 2.88 (+0.09), NES: 3.52 (-0.15), TZOO: 13.06 (-0.02), WLT: 0.57 (-0.01), FXCM: 2.13 (+0.02), NNVC: 2.02 (-0.02), VLTC: 15.14 (-1.04), CYN: 93.19 (+0.06), ANR: 0.84 (-0.01), OTIC: 32.83 (unch), MHR: 2.34 (-0.07), EGLT: 10.34 (-0.27), NERV: 5.68 (+0.05), FFIV: 120.42 (+1.49), KEG: 2.15 (+0.03), CTP: 3.89 (+0.08), ENRJ: 1.75 (+0.05), LE: 29.96 (-0.13)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 10.38 (-0.10), BCRX: 10.62 (-0.09), CMRX: 39.73 (+0.65), HEB: 0.25 (+0.01), SRPT: 13.52 (+0.04), ABIO: 0.88 (+0.01), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02)
NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
PR Newswire - Thu Jan 22, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment. NNVC: 2.02 (-0.02)
NanoViricides announces purchase of common stock by insiders
M2 - Thu Jan 22, 5:29AM CST
Nanomaterials antiviral company NanoViricides (NYSE MKT:NNVC) said on Wednesday that its executives purchased 62,392 shares of its common stock in uncoordinated open market purchases during its open trading windows for insiders.
NNVC: 2.02 (-0.02)
NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock
PR Newswire - Wed Jan 21, 6:00AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders. NNVC: 2.02 (-0.02)
InsiderInsights.com Daily Round Up For 1/13/15: TWTR, WIW, STZ, ALL
InsiderInsights - at Seeking Alpha - Thu Jan 15, 8:54AM CST
STRM: 2.37 (-0.02), STZ: 115.99 (-1.30), CRDS: 2.58 (-0.02), PETX: 16.15 (+0.01), NNVC: 2.02 (-0.02), RM: 14.75 (+0.24), ALL: 70.88 (+0.06), TNET: 35.45 (-0.54), SFST: 17.51 (-0.24), AGEN: 6.08 (+0.21), GES: 18.14 (+0.11), WIW: 11.45 (unch), LRCX: 78.36 (+0.52), COST: 146.98 (-0.36), EBF: 14.00 (+0.17), TWTR: 51.73 (+0.41), JGW: 10.70 (+0.24), WIA: 11.60 (-0.04)
InsiderInsights.com Daily Round Up 1/12/15: BH, LTS, OPK, SNCR
InsiderInsights - at Seeking Alpha - Tue Jan 13, 9:51AM CST
AFAM: 44.60 (-0.22), RTN: 109.65 (+0.82), AERI: 34.42 (-0.70), MRD: 19.19 (+0.06), ADX: 14.17 (+0.06), LTS: 3.56 (unch), NNVC: 2.02 (-0.02), ARDX: 12.51 (-0.01), PANW: 153.87 (-0.50), CTRE: 13.39 (-0.24), PCTY: 31.29 (+0.64), BH: 396.99 (-5.47), WIW: 11.45 (unch), SNCR: 51.87 (+0.02), OPK: 14.60 (+0.17), UBA: 20.99 (-0.13), WIA: 11.60 (-0.04)
NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
PR Newswire - Wed Jan 07, 6:30AM CST
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, has completed the purchase of the state of the art cGMP-compliant Manufacturing and R&D facility located in Shelton, Connecticut, from Inno-Haven, LLC. NNVC: 2.02 (-0.02)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.01 (-0.02), NNVC: 2.02 (-0.02)
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.62 (-0.09), VSR: 3.51 (+0.05), TKMR: 18.38 (-0.14), NNVC: 2.02 (-0.02), INO: 10.38 (-0.10), CMRX: 39.73 (+0.65), APT: 2.19 (unch), HEB: 0.25 (+0.01), SRPT: 13.52 (+0.04), SMED: 6.84 (+0.01), PLX: 2.08 (+0.02), NLNK: 53.12 (-0.07), LAKE: 9.56 (-0.01), NSPH: 4.05 (+0.10)
